P. Bőhlen
Molecular Biology · 2000–2004
A researcher in the Science corpus: 5 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 16 citations into it; #17,194 of 17,773 by trust here, #5,137 by citations
- Cancer Research — 10 citations into it
Whom P. Bőhlen trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts P. Bőhlen overall
Papers from P. Bőhlen's perspective
Ordered by how strongly the researchers P. Bőhlen trusts endorse each paper. Same corpus, a different order for every researcher.
- Tumor angiogenesis: past, present and the near future. (Carcinogenesis)
- Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells (Journal of Experimental Medicine)
- Regulation of angiogenesis via vascular endothelial growth factor receptors. (Cancer Research)
- Role of vascular endothelial growth factor in regulation of physiological angiogenesis. (American Journal of Physiology - Cell Physiology)
- Mechanisms of angiogenesis and arteriogenesis (Nature Medicine)
- Angiogenesis in cancer and other diseases (Nature)
- Hematopoietic stem cell quiescence maintained by p21cip1/waf1. (Science)
- G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4 (Nature Immunology)
- Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. (Cell)
- The anti-angiogenic basis of metronomic chemotherapy (Nature Reviews. Cancer)
Their papers
- Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment (2002) — 684 citations
- Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 (2002) — 1,130 citations
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity (2000) — 610 citations
- Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis (2004) — 811 citations
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (2000) — 753 citations